Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
NCT00322517
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasms
Interventions
DRUG:
SU014813
Sponsor
Pfizer